Rituximab for relapsing-remitting multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  He, Dian ^a   Guo, Rui ^b   Zhang, Fubo ^c   Zhang, Chao ^b   Dong, Shuai ^b   Zhou, Hongyu ^d  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b Sixth People's Hospital of Jinan   (China)

^c Department of Neurology   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHILL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMORAL IMMUNE DEFICIENCY; MONOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SINUSITIS; SOCIOECONOMICS; SORE THROAT; SYSTEMATIC REVIEW; THROAT IRRITATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADULT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897368225     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009130.pub3     Document Type: Review

References (34)

1. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al.B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine 2008;358(7):676-88.
2. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al.Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Annals of Neurology 2008;63(6):803.
3. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al.Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010;74(23):1860-7.
4. A Double Blinded, Placebo Controlled, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis. Ongoing study February 2012.
5. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al.B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. Journal of Experimental Medicine 2012;209(5):1001-10.
6. National Cancer Institute. The NCI Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed 28 October 2013).
7. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013;8(7):e66308.
8. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al.Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47(1):129-39.
9. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129(3):606-16.
10. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology 2006;180(1-2):63-70.
11. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al.Complement activation determines the therapeutic activity of rituximab in vivo. Journal of Immunology 2003;171(3):1581-7.
12. Duddy M, Bar-Or A. B-cells in multiple sclerosis. The International MS Journal 2006;13:84-90.
13. U.S. Food, Drug Administration. Rituxan full prescribing information 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5414lbl.pdf (Accessed 28 October 2013).
14. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al.Immunomodulators and immunosuppressants for multiple sclerosis: A network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD008933.pub2]
15. Fischer JS, La Rocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5(4):251-9.
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org.
17. Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Multiple Sclerosis 2012;18(2 Suppl):7-15.
18. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):11-25.
19. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
20. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
21. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al.Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Archives of Neurology 2009;66(8):1016-20.
22. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50(1):121-7.
23. Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patient's perspective. Patient 2012;5(1):57-69.
24. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, et al.Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Archives of Neurology 2010;67(6):707-14.
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-6.
26. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011;69(2):292-302.
27. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-31.
28. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al.Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45.
29. The Nordic Cochrane Centre, The CochraneCollaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The CochraneCollaboration, 2013.
30. Taupin P. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121. Expert Opinion on Therapeutic Patents 2011;21(1):111-4.
31. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of Life Research 1995;4(3):187-206.
32. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36).I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
33. Waubant E. Spotlight on anti-CD20. The International MS Journal 2008;15(1):19-25.
34. He D, Zhou H, Han W, Zhang S. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD009130.pub2]